Abstract:Abstract Background Kirsten rat sarcoma (KRAS) and mutant KRASG12D have been implicated in human cancers, but it remains unclear whether their activation requires ubiquitination. This study aimed to investigate whether and how F-box and leucine-rich repeat 6 (FBXL6) regulates KRAS and KRASG12D activity in hepatocellular carcinoma (HCC). Methods We constructed transgenic mouse strains LC (LSL-Fbxl6KI/+;Alb-Cre, n = 13), KC (LSL-KrasG12D/+;Alb-Cre, n = 10) and KLC (LSL-KrasG12D/+;LSL-Fbxl6KI/+;Alb-Cre, n = 12) mice, and then monitored HCC for 320 d. Multiomics approaches and pharmacological inhibitors were used to determine oncogenic signaling in the context of elevated FBXL6 and KRAS activation. Co‑immunoprecipitation (Co-IP), Western blotting, ubiquitination assay and RAS activity detection assay were employed to investigate the underlying molecular mechanism by which FBXL6 activates KRAS. The pathological relevance of the FBXL6/KRAS/extracellular signal-regulated kinase (ERK)/mammalian target of rapamycin (mTOR)/proteins of relevant evolutionary and lymphoid interest domain 2 (PRELID2) axis was evaluated in 129 paired samples from HCC patients. Results FBXL6 is highly expressed in HCC as well as other human cancers (P < 0.001). Interestingly, FBXL6 drives HCC in transgenic mice. Mechanistically, elevated FBXL6 promotes the polyubiquitination of both wild-type KRAS and KRASG12D at lysine 128, leading to the activation of both KRAS and KRASG12D and promoting their binding to the serine/threonine-protein kinase RAF, which is followed by the activation of mitogen-activated protein kinase kinase (MEK)/ERK/mTOR signaling. The oncogenic activity of the MEK/ERK/mTOR axis relies on PRELID2, which induces reactive oxygen species (ROS) generation. Furthermore, hepatic FBXL6 upregulation facilitates KRASG12D to induce more severe hepatocarcinogenesis and lung metastasis via the MEK/ERK/mTOR/PRELID2/ROS axis. Dual inhibition of MEK and mTOR effectively suppresses tumor growth and metastasis in this subtype of cancer in vivo. In clinical samples, FBXL6 expression positively correlates with p-ERK (χ2 = 85.067, P < 0.001), p-mTOR (χ2 = 66.919, P < 0.001) and PRELID2 (χ2 = 20.891, P < 0.001). The Kaplan–Meier survival analyses suggested that HCC patients with high FBXL6/p-ERK levels predicted worse overall survival (log‑rank P < 0.001). Conclusions FBXL6 activates KRAS or KRASG12D via ubiquitination at the site K128, leading to activation of the ERK/mTOR/PRELID2/ROS axis and tumorigenesis. Dual inhibition of MEK and mTOR effectively protects against FBXL6- and KRASG12D-induced tumorigenesis, providing a potential therapeutic strategy to treat this aggressive subtype of liver cancer.

Small GTPase RBJ mediates nuclear entrapment of MEK1/MEK2 in tumor progression.

Small GTPase RBJ Mediates Nuclear Entrapment of MEK1/MEK2 in Tumor Progression

Mechanisms of Cytoplasmic β-Catenin Accumulation and Its Involvement in Tumorigenic Activities Mediated by Oncogenic Splicing Variant of the Receptor Originated from Nantes Tyrosine Kinase

RBPJ Inhibits the Movability of Endometrial Carcinoma Cells by Mir-155/Nf-κb/ros Pathway

β-Arrestin-1-dependent activation of extracellular signal-regulated kinases in RON receptor-mediated tumorigenic activities in colon cancer cells

Sequential Inductions of the ZEB1 Transcription Factor Caused by Mutation of Rb and then Ras Proteins Are Required for Tumor Initiation and Progression

RBBP6, a RING Finger-Domain E3 Ubiquitin Ligase, Induces Epithelial–mesenchymal Transition and Promotes Metastasis of Colorectal Cancer

RKTG Sequesters B-Raf to the Golgi Apparatus and Inhibits the Proliferation and Tumorigenicity of Human Malignant Melanoma Cells.

Extracellular Signal-Regulated Kinase 8-Mediated C-Jun Phosphorylation Increases Tumorigenesis of Human Colon Cancer

Extracellular signal-regulated kinases modulate DNA damage response - a contributing factor to using MEK inhibitors in cancer therapy.

The ZEB1 Transcription Factor Acts in a Negative Feedback Loop with Mir200 Downstream of Ras and Rb1 to Regulate Bmi1 Expression

Bidirectional Signals Transduced by TOPK-ERK Interaction Increase Tumorigenesis of HCT116 Colorectal Cancer Cells

RBPJ maintains brain tumor–initiating cells through CDK9-mediated transcriptional elongation

ARHGEF19 Interacts with BRAF to Activate MAPK Signaling During the Tumorigenesis of Non‐small Cell Lung Cancer

Aberrant MEK5 Signalling Promotes Renal Cancer Development via mTOR Activation

TMPRSS2-ERG Promotes the Initiation of Prostate Cancer by Suppressing Oncogene-Induced Senescence

ERK/MAPK signalling pathway and tumorigenesis

An Rb1-dependent amplification loop between Ets1 and Zeb1 is evident in thymocyte differentiation and invasive lung adenocarcinoma

RDM1 promotes neuroblastoma growth through the RAS-Raf-MEK-ERK pathway.

Knockdown of RBM15 inhibits tumor progression and the JAK-STAT signaling pathway in cervical cancer

Elevated FBXL6 Activates Both Wild-Type KRAS and Mutant KRASG12D and Drives HCC Tumorigenesis Via the ERK/mTOR/PRELID2/ROS Axis in Mice